Amendments to the Claims

1. (Currently amended) A compound of formula (**I**):



(I)

or pharmaceutically acceptable salts, or solvates~~, or N_{10}-C_{11} imine bond prodrugs~~ thereof, wherein:

R^6, R^7 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, N[[H]]RR', nitro, Me_3Sn and halo;

where R and R' are independently selected from C_{1-7} alkyl, heterocyclyl having 3 to 20 ring atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteratoms independently selected from the group consisting of N, O and S;

R^8 is selected from H, R, OH, OR, SH, SR, NH_2, NHR, N[[H]]RR', nitro, Me_3Sn and halo, or the compound is a dimer with each monomer being of formula (**I**), where the R^8 groups of each monomers form together a dimer bridge having the formula -X-R''-X- linking the monomers, where R'' is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms selected from the group consisting of O, S, and NH, and/or aromatic rings selected from the group consisting of benzene and pyridine, and each X is independently selected from O, S, or NH;

or any pair of adjacent groups from R^6 to R^9 together form a group -O-$(CH_2)_p$-O-, where p is 1 or 2; and

R^2 is a napthyl group, optionally substituted by one or more substituents selected from the group consisting of halo, C_{1-7} alkyl, C_{1-7} alkoxy, C_{3-20} heterocyclyl, C_{5-20} heterocyclyl, , and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteratoms independently selected from the group consisting of N, O and S~~;~~.

2. Cancelled.

3. Cancelled.

4. (Previously presented) A compound according to claim 1, wherein R^9 is H.

5. (Previously presented) A compound according to claim 1, wherein R^6 is H.

6. (Previously presented) A compound according to claim 1, wherein R^7 and R^8 (when the compound is not a dimer) are selected from OMe and OCH_2Ph.

7. Cancelled.

8. (Previously presented) A pharmaceutical composition containing a compound of claim 1, and a pharmaceutically acceptable carrier or diluent.

9. Cancelled.

10. (Previously presented) A method of treatment of melanomas, or breast, renal, or lung cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of claim 1.

11. (Currently amended) A compound of formula (II)



(II)

wherein

R^2 is a napthyl group, optionally substituted by one or more substituents selected from the group consisting of halo, C_{1-7} alkyl, C_{1-7} alkoxy, C_{3-20} heterocyclyl, C_{5-20} heterocyclyl, , and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteratoms independently selected from the group consisting of N, O and S;

R^6, R^7 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', nitro, Me_3Sn and halo;

R^8 is selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', nitro, Me_3Sn and halo, or the compound is a dimer with each monomer being of formula (II), where the R^8 groups of each monomers form together a dimer bridge having the formula -X-R''-X- linking the monomers, where R'' is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms selected from the group consisting of O, S, and NH, and/or aromatic rings selected from the group consisting of benzene and pyridine, and each X is independently selected from O, S, or NH;

or any pair of adjacent groups from R^6 to R^9 together form a group $-O-(CH_2)_p-O-$, where p is 1 or 2;

R_{10} is selected from:

(a) $4\text{-}NO_2\text{-}C_6H_4\text{-}CH_2$-;

(b) $2\text{-}NO_2$-, 4,5-diMeO-$C_6H_4\text{-}CH_2$;

(c) $C_6H_5\text{-}CH_2$-; and

(d) $Me\text{-}SO_2\text{-}C_2H_4$-;

R_{11} is selected from OH, OR or SR; and

R and R' are independently selected from C_{1-7} alkyl, heterocyclyl having 3 to 20 ring atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more

heteratoms independently selected from the group consisting of N, O and S ~~according to claim 1, wherein the N_{10}-C_{11} imine bond prodrug comprises a nitrogen protecting group on N_{10} which can be removed *in vivo* and a hydroxyl, ester or thioester group on C_{11}~~.

12. Cancelled.